Katharine Nicholson
@KNicholsonMD
Followers
393
Following
103
Media
11
Statuses
150
ALS clinician researcher at Massachusetts General Hospital with specific interests in markers of disease in early familial ALS and the gut microbiome in ALS
Joined December 2018
Exciting to provide clinical and research updates to our patients- from Amylyx and Tofersen to Prevent ALS!
0
2
12
Stole this from an excellent talk by @KNicholsonMD - who can tell me how to have a diet that supplements the things in blue, and suppresses the things in orange?
0
1
6
Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS | Biogen
investors.biogen.com
The Investor Relations website contains information about Biogen's business for stockholders, potential investors, and financial analysts.
0
0
2
Join Dr. Richard Bedlack @dukealsclinic and Dr. Merit Cudkowicz @MGHNeurology for Part 6 of the #ALS Drug Development Webinar Series on September 15th https://t.co/fSuOEQ1YGY
0
6
8
30 signed Lou Gehrig Day baseballs across MLB + a one-of-a kind experience. All net proceeds will benefit the Expanded Access Protocol Program (EAP) at the Sean M. Healey & AMG Center for ALS. The #LouGehrigDay Auction is live now: https://t.co/ey3AXpCunw
11
54
269
A big heartfelt thank you to @RepAuchincloss for taking time out of his busy schedule today to meet with me and my family. I truly believe he will do everything in his power to help the ALS community. As I said today WE NEED YOU! Thank you! ❤️
4
9
46
I can't emphasize this enough-the ALS Principles are the boundaries that people living with ALS have needed. 'What we allow will continue' and we must make sure we are building clear paths towards treatments for a horrendous disease, always working together so we get there faster
The Morris ALS Principles were developed by those most impacted by ALS as a social contract that will drive a path forward. They show how each of us can do better so that treatments and cures are a reality and not an empty promise.
4
13
73
Join us this Friday at 3:30 PM ET for Part 4 of the #ALS Drug Development Webinar Series: Site Considerations https://t.co/QeU8mZQ6Pk
0
3
2
Join us on May 17th at 2 PM ET for An Update on the CENTAUR Trial: a Trial of AMX0035 in ALS https://t.co/s99p9CdVnS
1
6
11
We’re excited to announce our intention to submit a Marketing Authorization Application (MAA) for AMX0035 for the treatment of #ALS to the European Medicines Agency & the start of a Phase 3 trial in Europe & the U.S.
businesswire.com
Amylyx Pharmaceuticals today provided an update on its plans to advance AMX0035 through the clinical development process for the treatment of ALS.
8
20
60
Today, we are excited to share news of our plans to submit a New Drug Submission for AMX0035 for the treatment of #ALS with Health Canada in the first half of 2021. This decision is based on the positive clinical data from the CENTAUR trial, and feedback from Health Canada.
23
62
279
2020 was a turning point for #ALS research- thank you to our supporters and people who inspire our research @iamalsorg @sandymorris333 @alsassociation @MDAorg @MGHNeurology
4
22
77
If the ALSFRS-R is the gold standard, it is a chocolate coin in gold foil masquerading as such and someday will be devoured by more objective measures - a patient with a flair for the dramatic #alsmndsymp @MGHNeurology @KNicholsonMD
So can we stop using this as the “gold standard” for measuring treatment efficacy and progression? #alsmndsymp 4/4
0
3
21
In addition, a team from Mass General including @sheenachew, @PaganoniMDPhD, @LidiaMouraNVL and @KNicholsonMD has a poster on patient-reported outcomes and the ALSFRS-R and ABC scales. Download clinical trial poster abstracts here:
1
3
9
Exciting new data presented by @PaganoniMDPhD from @AmylyxPharma and @ENCALS collaboration to predict a broader ALS population may have an up to 11.5 mo survival benefit from AMX0035! @MGHNeurology #alsmndsymp #HealeyHope
0
2
15
Today at the Intl. Symposium on ALS/MND check out the latest findings from @GSVLab together with @tpetrozziello assessing how DRP1 and tau affect mitochondrial fragmentation in ALS. More info: https://t.co/D22xqv3igG
#HealeyHope #ALSSymp
0
3
6
Thank you @PaganoniMDPhD @AmylyxPharma for presenting positive Centaur phase 2 results at #alsmndsymp with BOTH significant survival and functional benefits seen. Very exciting results for a well designed trial! Thank you to patients and caregivers from the study! @MGHNeurology
1
6
25
A consistent robust treatment effect on CSF biomarkers of neuroinflammation/neuronal injury (reduced) and neuroprotection (increased) was seen in the Phase 3 @BrainstormCell trial. Important learnings for the entire ALS field! @MGHNeurology #alsmndsymp #HealeyHope
4
29
56
The Symposium on ALS/MND poster session on genetics & genomics features work on early markers of disease in familial ALS from @KNicholsonMD, Dr. James Berry, and collaborators at @WashUNeurology & @MayoClinicNeuro Jacksonville. #HealeyHope #ALSSymp
0
3
6